Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL78522 | 0.97 | HRH1 (0.34) | HRH1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12555812 | 0.91 | HRH1 (0.31) | HRH1 | |
| SCHEMBL738380 | 0.85 | — | — | |
| SCHEMBL3631001 | 0.85 | — | — | |
| SCHEMBL12651661 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL31321233 | 0.83 | HTR2C (0.33) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL18036210 | 0.83 | HTR2C (0.33) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL31321244 | 0.83 | HTR2C (0.33) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL18036209 | 0.83 | HTR2C (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23651491 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116925289-A | Environment-friendly chitin-based foam stabilizer for geothermal well drilling fluid and preparation method and application thereof | 中国石油大学(华东) | 2023-10-24 | — | — | CN | claimed |
| CN-116731326-A | High-temperature-resistant high-salt-resistant Pickering foam stabilizer for geothermal well drilling fluid and preparation method thereof | 中国石油大学(华东) | 2023-09-12 | — | — | CN | claimed |
| CN-115916759-A | Substituted quinazoline compound, preparation method, pharmaceutical composition and application thereof | 南京红云生物科技有限公司 | 2023-04-04 | — | — | CN | claimed |
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | ORGANON R&D FINLAND LTD. (FI) | 2026-05-26 | — | — | US | disclosed |
| US-12606561-B2 | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2026-04-21 | — | — | US | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-20250333418-A1 | PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NOVO NORDISK AS (DK) | 2025-10-30 | — | — | US | disclosed |
| US-20250257057-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | GOLGI NEUROSCIENCES S.R.I. (IT) | 2025-08-14 | — | — | US | disclosed |
| EP-4334289-B1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Organon R&D Finland Oy (FI) | 2025-06-25 | — | — | EP | disclosed |
| US-12258337-B2 | Bicyclic CX3CR1 receptor agonists | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-03-25 | — | — | US | disclosed |
| US-12162848-B2 | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-10 | — | — | US | disclosed |
| US-20070072844-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ARENA PHARMACEUTICALS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS (US) | 2007-03-29 | — | — | US | disclosed |
| US-7169784-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7163943-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | ARENA PHARMACEUTICALS, INC. | 2006-07-13 | — | — | US | disclosed |
| US-3988317-A | ANTICHOLESTEROL AGENTS | BOEHRINGER MANNHEIM G.M.B.H. (DT) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606561-B2 | Substituted pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDK6, CDKL1, CDK3 | HRH1 202/4885SLC6A2 4747/4885SLC6A4 4701/4885 |
| US-12258337-B2 | Bicyclic CX3CR1 receptor agonists | CX3CR1, CCR2, CCR5 | HRH1 494/4885SLC6A2 3547/4885SLC6A4 2786/4885 |
| US-20070072804-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | HRH1 1174/4885SLC6A2 804/4885SLC6A4 223/4885 |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | HRH1 691/4885SLC6A2 4796/4885SLC6A4 4750/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | HRH1 1097/4885SLC6A2 3822/4885SLC6A4 3978/4885 |
| US-20250333418-A1 | PURINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | CNR1, CNR2, P2RY1 | HRH1 193/4885SLC6A2 116/4885SLC6A4 106/4885 |
| US-20250257057-A1 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | CX3CR1, CCR2, CCR5 | HRH1 494/4885SLC6A2 3547/4885SLC6A4 2786/4885 |
| US-12162848-B2 | Inhibitors of protein tyrosine phosphatase, compositions, and methods of use | PTPN2, PTPN22, PTPN5 | HRH1 4592/4885SLC6A2 918/4885SLC6A4 1822/4885 |
| US-20060154866-A1 | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level | GLP1R, GPR119, GIPR | HRH1 1174/4885SLC6A2 804/4885SLC6A4 223/4885 |
| US-20070073062-A1 | Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof | ACE, ACE2, AGTR2 | HRH1 1243/4885SLC6A2 3499/4885SLC6A4 4203/4885 |
| US-20070072844-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | HRH1 1665/4885SLC6A2 1383/4885SLC6A4 1338/4885 |
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | AKR1C3, AKR1C4, AKR1C2 | HRH1 1377/4885SLC6A2 2637/4885SLC6A4 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.